Skip to main content
Log in

Plasma concentration of α-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The plasma concentrations of free α-methyldopa and methyldopa sulphate conjugate were measured in 7 hypertensive patients with normal renal function following α-methyldopa (1 g) orally. Five of these patients subsequently received α-methyldopa ethyl ester (250 mg) (methyldopate) intravenously and two further patients received 250 mg of α-methyldopa intravenously. After oral administration a large amount of total plasma α-methyldopa was present as sulphate conjugate. There were wide interindividual differences in the ratio of free: conjugated α-methyldopa in plasma (ratio at 4 hours ranged from 3.73 – 0.83) suggesting that individual differences in the extent of sulphate conjugation may occur. There was no close correlation between the degree of conjugation and the fall in arterial pressure. At all time intervals examined, plasma concentrations were higher following intravenous α-methyldopa than α-methyldopate. The plasma concentration of α-methyldopa (free and esterified) 60 minutes after i.v. α-methyldopate was 1.7±0.3 µg/ml wile at the same time after the same dose of methyldopa by the same route the mean concentration was 5.9 µg/ml. Although small amounts of sulphate conjugate were detected after i.v. α-methyldopate, insignificant quantities of conjugate were found after i.v. α-methyldopa. The average fall in mean arterial pressure was 27 mm Hg following i.v. α-methyldopa but only 2.7 mm Hg following α-methyldopate. These results suggest that sulphate conjugation of α-methyldopa occurs in the gastrointestinal tract during absorption. Hydrolysis of α-methyldopa ethyl ester does not appear to be instantaneous and pharmacokinetic differences between the ester and free α-methyldopa have been demonstrated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Oates, J.A., Gillespie, L., Udenfriend, S., Sjoerdsma, A.: Decarboxylase inhibition and blood pressure reduction by α-methyl-3,4-dihydroxy-DL-phenylalanine. Science131 1890–1891 (1960)

    Google Scholar 

  2. Sourkes, T.L., Murphy, G.F., Chavez-Lara, B.: A metabolic study of α-methyl-β-(3,4-dihydroxy-phenyl)-DL alanine in man. J. Med. Pharm. Chem.5 204–210 (1962)

    Google Scholar 

  3. Gillespie, L., Oates, J.A., Crout, J.R., Sjoerdsma, A.: Clinical and chemical studies with α-methyldopa in patients with hypertension. Circulation25 281–291 (1962)

    Google Scholar 

  4. Sjoerdsma, A., Vendsalu, A., Engelman, K.: Studies on the metabolism and mechanism of action of methyldopa. Circulation28 492–502 (1963)

    Google Scholar 

  5. Prescott, L.F., Buhs, R.P., Beattie, J.O., Speth, O.C., Trenner, N.R., Lasagna, L.: Combined clinical and metabolic study of the effects of alpha methyldopa on hypertensive patients. Circulation34 308–321 (1966)

    Google Scholar 

  6. Dollery, C.T., Harington, M.: Methyldopa in hypertension: clinical and pharmacological studies. Lancet1962 I 759–763

    Google Scholar 

  7. Au, W.Y.U., Dring, L.G., Grahame-Smith, D.G. Isaac, P., Williams, R.T.: The metabolism of14C labelled α-methyldopa in normal and hypertensive human subjects. Biochem. J.129 1–10 (1972)

    Google Scholar 

  8. Buhs, R.P., Beck, J.L., Speth, O.C., Smith, J.L., Trenner, N.R., Cannon, P.J., Laragh, J.H.: Metabolism of methyldopa in hypertensive human subjects. J. Pharmacol. exp. Ther.143 205–214 (1964)

    Google Scholar 

  9. Roy, A.B.: The synthesis and hydrolysis of sulfate esters. Advanc. Enzymol.22 205–235 (1960)

    Google Scholar 

  10. Conolly, M.E., Davies, D.S., Dollery, C.T., Morgan, C.D., Paterson, J.W., Sandler, M.: Metabolism of isoprenaline in dog and man. Brit. J. Pharmacol.46 458–472 (1972)

    Google Scholar 

  11. Anton, A.H., Sayre, D.F.: Study of the factors affecting the aluminium oxide-trihydroxy-indole procedure for the analysis of catecholamines. J. Pharmacol. exp. Ther.138 360–375 (1962)

    Google Scholar 

  12. Laverty, R., Taylor, K.M.: The fluorometric assay of catecholamine and related compounds. Improvement and extension of the hydroxy-indole technique. Ann. Biochem.22 269–297 (1962)

    Google Scholar 

  13. Rowland, M.: Influence of route of administration on drug availability. J. pharm. Sci.61 70–74 (1972)

    Google Scholar 

  14. Stenbaek, O., Myhre, E., Brodwall, E.K., Hansen, T.: Hypotensive effect of methyldopa in renal failure associated with hypertension. Acta. med. scand.191 333–337 (1972)

    Google Scholar 

  15. Schrader, K., Brass, H., Renner, D.: Zur Pharmacokinetik von α-Methyldopa bei Niereninsuffizienz. Klin. Wschr.49 1329–1334 (1971)

    Google Scholar 

  16. Henning, M.: Studies on the mode of action of α-methyldopa. Acta physiol. scand. Suppl.322 1–37 (1969)

    Google Scholar 

  17. Finch, L., Haeusler, G.: Further evidence for a central hypotensive action of alpha methyldopa. Brit. J. Pharmacol.45 167–168 P (1972)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saavedra, J.A., Reid, J.L., Jordan, W. et al. Plasma concentration of α-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester. Eur J Clin Pharmacol 8, 381–386 (1975). https://doi.org/10.1007/BF00562310

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00562310

Key words

Navigation